Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.

Argenx discontinued its Phase 3 UplighTED studies evaluating efgartigimod for thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility, despite a favorable safety profile.

4D Molecular Therapeutics announced the appointment of Kristian Humer as Chief Financial Officer, bringing over two decades of finance and biotechnology experience to support the company's late-stage clinical development and commercial planning.

Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

Viridian Therapeutics reported Q2 2025 results, highlighting progress in thyroid eye disease treatment with veligrotug, securing FDA Breakthrough Therapy Designation and a $70 million licensing deal with Kissei Pharmaceutical, while experiencing increased research expenses and net losses.

The global ophthalmic disease therapeutics market is projected to grow significantly due to factors like the introduction of innovative treatments, rising disposable incomes, and expanding healthcare infrastructure. The market is segmented by indication, therapies, and distribution channel.

The thyroid eye disease market is expected to show good positive growth by 2034, driven by new product launches, a robust pipeline of emerging therapies, and an increase in the geriatric population.

7 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Viridian Therapeutics, presenting an average target of $26.57, a high estimate of $31.00, and a low estimate of $20.00. A decline of 15.38% from the prior average price target is evident in the current average. Understanding Analyst Ratings: A Comprehensive Breakdown The standing of Viridian Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Richard Law Goldman Sachs Announces Buy $23.00 - Douglas Tsao HC Wainwright & Co. Lowers Buy $27.00 $37.00 Leland Gershell Oppenheimer Lowers Outperform $31.00 $36.00 Kalpit Patel B. Riley Securities Lowers Neutral $20.00 $25.00 Serge Belanger Needham Maintains Buy $30.00 - Kalpit Patel B. Riley Securities Lowers Buy $25.00 $29.00 Serge Belanger Needham Maintains Buy $30.00 $30.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating ...Full story available on Benzinga.com

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 26.17% and 10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Across the recent three months, 4 analysts have shared their insights on Viridian Therapeutics (NASDAQ:VRDN), expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.25, a high estimate of $40.00, and a low estimate of $30.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.72%. Exploring Analyst Ratings: An In-Depth Overview In examining recent analyst actions, we gain insights into how financial experts perceive Viridian Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Serge Belanger Needham Maintains Buy $30.00 $30.00 Douglas Tsao HC Wainwright & Co. Maintains Buy $37.00 - Laura Chico Wedbush Raises Outperform $40.00 $39.00 Serge Belanger Needham Maintains Buy $30.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Viridian Therapeutics. ...Full story available on Benzinga.com